Harvard Bioscience (HBIO) Other financing activities (2020 - 2026)

Harvard Bioscience (HBIO) has 7 years of Other financing activities data on file, last reported at $150000.0 in Q1 2026.

• On a quarterly basis, Other financing activities changed N/A year-over-year to $150000.0 in Q1 2026; TTM through Mar 2026 was $197000.0, a 46.03% decrease from a year earlier, with the FY2025 full-year figure at $47000.0, down 87.63% from the prior year.
• Other financing activities for Q1 2026 stood at $150000.0, up from $1000.0 in the prior quarter.
• Over the last five years, Other financing activities for HBIO reached as high as $620000.0 in Q2 2023 and fell as low as $1000.0 in Q4 2025.
• Historically, Other financing activities has averaged $148857.1 across 5 years, with a median of $127000.0 in 2023.
• Across the five-year window, Other financing activities soared 235.48% in 2023 and sank 99.38% in 2025, its largest moves.
• Year by year, Other financing activities stood at $231000.0 in 2022, then fell by 10.82% to $206000.0 in 2023, then fell by 21.84% to $161000.0 in 2024, then sank by 99.38% to $1000.0 in 2025, then jumped by 14900.0% to $150000.0 in 2026.
• Per Business Quant data, the three most recent Other financing activities figures were $150000.0 in Q1 2026, $1000.0 in Q4 2025, and $46000.0 in Q2 2025.